Madrigal Pharmaceuticals
New York, NY, USA
Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy, Rezdiffra (resmetirom), was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. Medical Science Liaison, Endocrinology Position Summary The Medical Science Liaison, Endocrinology (MSL) is a field-based medical role focused on building and maintaining scientific partnerships with healthcare professionals (HCPs) and key decision-makers through non-promotional, evidence-based scientific exchange. The MSL will serve as a key liaison for Madrigal’s clinical and scientific efforts in MASH/NASH, engaging thought leaders (TLs), academic...